单位:[1]College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China[2]State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China[3]Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing 100084, China[4]Clinical Laboratory, China-Japan Friendship Hospital, Beijing 100029, China
A once-in-a-century global public health crisis, the COVID-19 pandemic has damaged human health and world economy greatly. To help combat the virus, we report a self-resetting molecular probe capable of repeatedly detecting SARS-CoV-2 RNA, developed by orchestrating a fuel dissipative system via DNA nanotechnology. A set of simulation toolkits was utilized to design the probe, permitting highly consistent signal amplitudes across cyclic detections. Uniquely, full width at half maximum regulated by dissipative kinetics exhibits a fingerprint signal suitable for high confidential identifications of single-nucleotide variants. Further examination on multiple human-infectious RNA viruses, including ZIKV, MERS-CoV, and SARS-CoV, demonstrates the generic detection capability and superior orthogonality of the probe. It also correctly classified all the clinical samples from 55 COVID-19 patients and 55 controls. Greatly enhancing the screening capability for COVID-19 and other infectious diseases, this probe could help with disease control and build a broader global public health agenda. (c) 2021 Elsevier Ltd. All rights reserved.
基金:
State Key Research Development Program of ChinaState Key Development Program for Basic Research of China [2019YFC1200500, 2019YFC1200502]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31971361]; Natural Science Foundation of Beijing MunicipalityBeijing Natural Science Foundation [5212013]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities; National Mega-project for Innovative Drugs [2019ZX09721001-007-002]; Research projects on biomedical transformation of China-Japan Friendship Hospital [XK-2020-08]